Month: September 2020

Amsterdam, September 25, 2020Press ReleaseHALF-YEAR RESULTS 2020: UNIBAIL-RODAMCO-WESTFIELD N.V.On September 25, 2020, Unibail-Rodamco-Westfield N.V. (“URW NV”) announced its 2020 half-year results and released its consolidated interim financial statements for the period ending June 30, 2020, which can be found on: https://www.urw-nv.com/en/investors/press-releases and as an attachment to this press release. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield (“URW”). URW SE consolidates URW NV and its controlled undertakings, and its 2020 half-year results represent a comprehensive overview of URW, and is available on: https://www.urw.com/en/investors/financial-information/financial-resultsFor further information, please contact:Investor...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Sept. 25, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) announces that the expiry date (the “Expiry Date”) for the warrants issued on August 28, 2020 and September 11, 2020 (the “Warrants”), with regard to its recent non-brokered private placement (see news releases dated August 28, 2020 and September 11, 2020), has been accelerated to 30 days from today’s date (for a new Expiry Date of October 25, 2020). The acceleration of the Expiry Date is due to a trigger event which occurred due to the closing price of the common shares being equal or greater than $1.25 for a period of five (5) consecutive trading days,...

 — Jyseleca®  Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program —Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1RA is a chronic, progressive, systemic, inflammatory...

— Jyseleca® laat duurzame werkzaamheid en een consistent veiligheidsprofiel zien bij reumatoïde artritis tot 52 weken in fase 3 klinisch ontwikkelingsprogramma —Foster City, Calif., & Mechelen, België, 25 september 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) en Galapagos NV (Euronext & Nasdaq: GLPG) kondigen vandaag aan dat de Europese Commissie (EC) de handelsvergunning voor Jyseleca® (filgotinib 200 mg en 100 mg tabletten) heeft verleend, een eenmaal daagse, orale, JAK1 remmer voor de behandeling van volwassenen met matige tot ernstige actieve reumatoïde artritis (RA, in de volksmond reuma) die eerder onvoldoende hebben gereageerd op of intolerant zijn voor ziekte-modificerende anti-reumatische geneesmiddelen (DMARDs). Jyseleca mag worden gebruikt als monotherapie of in combinatie met methotrexaat (MTX).1RA...

Regulated InformationResults of the general shareholders’ meetings held on 24 September 202025 September 2020 at 19.00 CESTNyrstar NV (the “Company”) held general shareholders’ meeting (“GM”) in Antwerp yesterday.The GM did not have an attendance quorum requirement for the item on the agenda. The shareholders approved the item on the agenda of the GM.About NyrstarThe Company is incorporated in Belgium and, following completion of the recapitalisation/restructuring has a 2% shareholding in the Nyrstar group. The Company is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.beFor further information contact:Anthony Simms –       Head of External Affairs and Legal      M: +41 79 722 2152  anthony.simms@nyrstar.comAttachmentGM result...

Gereglementeerde informatieResultaten van de algemene aandeelhoudersvergaderingen gehouden op 24 september 202025 september 2020 om 19.00 uur CESTNyrstar NV (de “Vennootschap”) hield gisteren een algemene aandeelhoudersvergadering (“GM”) in Antwerpen.De AL had geen aanwezigheidsquorumvereiste voor het agendapunt. De aandeelhouders keurden het punt op de agenda van de AV goed.Over NyrstarDe Vennootschap werd opgericht in België en heeft, na voltooiing van de herkapitalisatie/herstructurering een 2% participatie in de Nyrstar Groep. De Vennootschap is op Euronext Brussels genoteerd onder het symbool NYR. Meer informatie vindt u op de website van Nyrstar: www.nyrstar.be.Neem voor meer informatie contact op met:Anthony Simms –       Head of External Affairs & Legal                M: +41 79 722 2152  anthony.simms@nyrstar.comBijlageGM...

RELEASE AND AVAILABILITY OF THE 2020 HALF-YEAR FINANCIAL REPORTClichy, France, September 25th, 2020The 2020 Half-Year Financial Report of SOCIÉTÉ BIC (Paris: BB) was sent to the A.M.F. – Autorité des Marchés Financiers (Paris Stock Exchange Authority) on September 25, 2020.The document is available on BIC’s website (www.bicworld.com).ABOUT BICBIC is a world leader in stationery, lighters, and shavers. For more than 75 years, the Company has honored the tradition of providing high-quality, affordable products to consumers everywhere. Through this unwavering dedication, BIC has become one of the most recognized brands and is a trademark registered worldwide. Today, BIC products are sold in more than 160 countries around the world and feature iconic brands such as Cello®, Conté®, BIC FlexTM, Lucky Stationery, Made For YOUTM, Soleil®, Tipp-Ex®,...

MISE A DISPOSITION DURAPPORT FINANCIER SEMESTRIEL 2020Clichy, France, le 25 septembre 2020Le Rapport Financier Semestriel 2020 de SOCIÉTÉ BIC (Paris : BB) a été déposé le 25 septembre 2020 auprès de l’Autorité des Marchés Financiers (AMF).Il peut être consulté sur le site Internet de BIC (www.bicworld.com).À PROPOS DE BICBIC est un des leaders mondiaux des articles de papeterie, des briquets et des rasoirs. Depuis plus de 75 ans, l’entreprise fabrique des produits de grande qualité accessibles à tous, partout dans le monde. Cette vocation a permis au Groupe de faire de sa marque, enregistrée dans le monde entier, l’une des plus reconnues. Aujourd’hui, les produits BIC® sont vendus dans plus de 160 pays et possèdent des marques emblématiques telles que Cello®, Conté®, BIC Flex™, Lucky Stationery, Made For YOU™, Soleil®, Tipp-Ex®, Wite-Out®....

Arna Grímsdóttir, framkvæmdastjóri lögfræðisviðs Reita, hefur óskað eftir að láta af störfum hjá félaginu og mun hún hverfa til annarra starfa þann 1. janúar nk. Við stöðu framkvæmdastjóra lögfræðisviðs tekur Ragnheiður Margrét Ólafsdóttir, en hún hefur starfað innan lögfræðisviðs Reita frá árinu 2014 og gegnt stöðu regluvarðar hjá félaginu frá sama tíma.Ragnheiður útskrifaðist frá lagadeild Háskóla Íslands á árinu 1998, starfaði hjá Hugverkastofunni frá 1998 – 2000 og á LEX lögmannsstofu frá 2000 – 2014 þar sem hún var einn meðeigenda frá árinu 2004. Ragnheiður er lögmaður með réttindi til málflutnings fyrir héraðsdómstólum, Landsrétti og Hæstarétti.Örnu Grímsdóttur eru þökkuð góð og farsæl störf fyrir Reiti undanfarin 11 ár og er henni óskað alls hins besta á nýjum vettvangi.